A new kind of sleeping pill, called suvorexant, was shown to be effective at helping people fall -- and stay -- asleep in clinical trials, according to research presented at the annual SLEEP2012 conference.
Excitement has been fueled over this pill because it works like no other sleeping pills currently approved by the Food and Drug Administration, providing one more drug option -- out of just a few -- for people who experience insomnia.
"Everyone is so excited [about suvorexant] because different pills work for different people," said Philip Gehrman, Ph.D., CBSM, clinical director of the Behavioral Sleep Medicine Program at the University of Pennsylvania, who was not involved with the new sleeping pill. "The more options we have that really act on different brain mechanisms, it really provides a whole new tool to our toolkit."
Suvorexant works by blocking brain chemical messengers call orexins, which are responsible for wakefulness. Gehrman told HuffPost that this mechanism is different from other hypnotics (sleeping pills), which work on other brain mechanisms, like the GABA neurotransmitter or melatonin.
Gehrman explained that if you think about the brain as having a "switch" between sleep and wakefulness, orexin helps to stabilize this switch so that you're all awake or all asleep.
"So it's not knocking you out like a sleeping pill does, it more stabilizes the switch," he told HuffPost.
However, Gehrman said he would still first try non-medication options for insomnia -- like cognitive behavioral treatments -- since there are always risks associated with medications. He also said that the drug also needs to be tested in more people before its full range of side effects are known.
Insomnia is a prevalent problem in the United States -- as many as 10 percent of Americans experience the condition, according to an earlier study in the journal The Lancet. And according to the Los Angeles Times, there were 56 million prescriptions for sleeping pills in 2008, which is an increase of 56 percent since 2004.
Suvorexant research was funded by Merck, and included more than 1,000 people in two trials over three months, Fox News reported.
The researchers compared the sleeping pill to placebo, and found that the pill seemed to work starting the first night a person took it, and worked equally well three months later. The people also didn't report many side effects, with side effects only including sleepiness and headache, WebMD reported.
For example, at three months, people who took suvorexant reported falling asleep 25.7 minutes faster, compared with 17.3 minutes for people who took the placebo, Fox News reported. People who took suvorexant also reported staying asleep 60.3 minutes longer, compared with 40.6 minutes longer by people who took the placebo.
"Nineteen minutes a night of more sleep for an entire month is a lot of additional sleep," study researcher Dr. Andrew D. Krystal, M.D., a psychiatry professor at Duke University Medical Center, told WebMD.
NBC News reported that research into the mechanisms of the drug began with study of the brains of narcoleptic dogs. The drug still needs to go to the Food and Drug Administration for approval, and it will need to be tested in more people to see if there are any more side effects, NBC News noted.
Earlier this year, a study came out in the journal BMJ Open showing that hypnotics, the name for sleeping pills, have been tied to an increased risk of death.
However, it's important to note that researchers only found a link between the two -- this study didn't prove that sleeping pills caused cancer or death.
CLARIFICATION: A previous version of this article did not clearly state how long it took for patients who took suvorexant to fall asleep, compared with placebo.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.